Cd37 immunotherapeutic combination therapies and uses thereof
AssigneeTrubion Pharmaceuticals, Inc.
InventorsCHARLES G. CERVENY, PETER A. THOMPSON
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for using CD37-specific binding molecules (such as a CD37-specific SMIP or antibody) in combination with mTOR inhibitors (such as rapamycin and derivatives or analogues thereof) or phosphatidylinositol 3-kinase (PI3K) inhibitors (such as p110δ-specific inhibitors or the like), which can be done concurrently or sequentially, to treat or prevent a B-cell related hyperproliferative disease, such as a lymphoma, carcinoma, myeloma, or the like.
Claims37
A method of reducing the number of B-cells or treating a disease or disorder associated with aberrant B-cell activity in a subject having or suspected having the disease or disorder, comprising treating a subject with a therapeutically effective amount of a CD37-specific binding molecule and a therapeutically effective amount of an mTOR or PI3K inhibitor.
-22. (canceled)
A composition, comprising:
- (a) a CD37-specific binding molecule, and
- (b) an mTOR or phosphatidylinositol 3-kinase (PI3K) inhibitor.
Dependencies are inferred from the claim text.